Covidien chief executive José Almeida sold 50,000 shares in his company last Friday, worth $3.6 million at the time he sold them, the Ireland-based medical device maker has disclosed.
Covidien won CE mark approval in Europe for its new acute care ventilation system.
Given Imaging's time as an independent company has come to a close. As expected, Irish medical device giant Covidien ($COV) has closed its $860 million buyout of the Israeli company known for its endoscopic PillCam capsules.
Covidien won the FDA's 510(k) clearance for a high-tech surgical stapling technology, adding another product to its growing portfolio.
Covidien's Japanese subsidiary, Covidien Japan Inc., received Shonin approval from the Japanese Ministry of Health, Labor and Welfare for its Endo GIA Reinforced Reload with Tri-Staple technology.
Device giant Covidien posted a slight boost in sales last quarter, as the recently pharma-free company prepares for what promises to be a transitional year.
Covidien's efforts to move its device business overseas continue as the Irish company opened a medical training and education center in Mumbai, India.
Covidien won U,S. FDA 510(k) clearance and a CE mark for a combination laparoscopic surgical device.
Covidien said it will abandon a renal denervation development program due to slower-than-expected market growth for the hypertension treatment. It's yet another industry setback for a medical device concept that only weeks ago was still generating enormous enthusiasm and expectations in the U.S.
Nearly four months after Covidien disclosed plans of selling its Confluent Surgical product line to Integra LifeSciences, the companies finalized the deal for $235 million in cash.